
Brepocitinib, a TYK2/JAK1 inhibitor, shows promise in treating psoriatic arthritis (PsA). A phase IIb study evaluated the efficacy and safety of oral brepocitinib in participants with moderately to severely active PsA over 52 weeks. At week 16, the brepocitinib groups exhibited significantly higher response rates, including a 20% improvement in disease activity (ACR20), ACR50/ACR70 response rates, PASI75/PASI90 improvement in psoriasis, and minimal disease activity.
Like
Save
Share